Jan. 13 at 9:35 PM
$ASRT We suffered through the worst of the reverse split----manipulation (and panic) down to the low
$8 range. Some investors sold out which probably needed to be done anyways. Others got cheap shares for sure. There is a positive now----the "value" that is here with ASRT is more apparent. A
$10 stock with:
$100M in cash is over
$15/share in cash to expand the pipeline. Their products are doing around
$18 in revenue/share. Sure they have a mix of misc products, but Rolvedon is for solid and same-day NCCN guideline approval would make it unique vs Neulesta and biosimilars. This stock was worth
$2 for sure pre-split. With fewer shares, the larger numbers make it easier to see. This is worth at least
$30 right now imo based on what they have let alone if they got Rolvedon growing. Would you buy a 70 cent stock that penny stock owners say should be worth
$2? How about buying a
$10 stock that is worth
$30? The numbers are the same but the risk seems less.
